3 Phosphoinositide Dependent Protein Kinase 1 Market
Global 3 Phosphoinositide Dependent Protein Kinase 1 Market Size, Share, and Trends Analysis Report by Drug Type (HCI-1708, AR-12, PHT-427, SNS 229, and Others), and by Application (Hospitals, Clinics, and Others) Forecast Period (2022-2028)
The global 3 phosphoinositide dependent protein kinase 1 market is anticipated to grow at a significant CAGR during the forecast period. PDK1 or 3 Phosphoinositide dependent kinase 1 is a key member of the AGC protein kinase family and is important in a variety of cellular functions which leads to the activation of the PI3K signalling pathway which is an event that is associated with the onset and progression of several human cancers. Thus, the major factor contributing to the growth of the market is the increasing prevalence of breast cancer across the globe. According to the World Health Organization (WHO), breast cancer is the most common cancer on the planet. Around 2.3 million women were diagnosed with breast cancer in 2020.
Impact of COVID-19 on Global 3 Phosphoinositide Dependent Protein Kinase 1 Market
The COVID-19 had a significant impact on the global 3 phosphoinositide dependent protein kinase 1 market. As breast cancer is the major factor attributing to the growth of the market, due to the implication of stringent lockdowns, there was a delay in diagnosis, treatment, and surgeries of various types of cancers globally. Hence, further decreasing the utilization and demand of the drugs used in the treatment of cancer. 3 phosphoinositide dependent protein kinase 1 is widely used in the treatment of breast cancer. Owing to the increasing number of cancer cases globally, the demand for the drug has been increased exponentially. Resultantly, the market is expected to cater “V” shaped recovery post COVID-19 pandemic.
Segmental Outlook
The global 3 phosphoinositide dependent protein kinase 1 market is segmented based on drug type and application. Based on the drug type, the market is sub-segmented into HCI-1708, AR-12, PHT-427, SNS 229, and others. Based on the application, the market is sub-segmented into hospitals, clinics, and others. The segments mentioned above can be customized as per requirements.
Global 3 phosphoinositide dependent protein kinase 1 Market Share by Application, 2021 (%)
The Hospital Segment is Expected to Hold a Prominent Share in the Global 3 Phosphoinositide Dependent Protein Kinase 1 Market
Among the application segment, the hospitals sub-segment is expected to hold considerable share in the global 3 phosphoinositide dependent protein kinase 1 market over the forecast period. Huge number of cancer diagnostic and treatment are being conducted within the hospitals which is major factor fuelling the growth of the market. The treatment of cancers such as breasts, lung, and others are conducted in hospitals and oncology centres, due to the presence of expert healthcare professionals and improved medical facilities. As a result, the consumption of 3 phosphoinositide dependent protein kinase 1 is more in hospitals due to the rising incidence of breast cancer globally. According to the American Cancer Society, breast cancer is the most common cancer in women in the US, around 30% (or 1 in 3) of all new female cancers each year.
Regional Outlooks
The global 3 phosphoinositide dependent protein kinase 1 market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. During the projection period, North America is expected to see significant market expansion. Due to the increasing cases of breast cancer in the US. and the presence of key pharmaceutical companies investing in the research and development activities.
Global 3 phosphoinositide dependent protein kinase 1 Market Growth, by Region 2022-2028
The North America Region is Anticipated to Hold a Prominent Share in the Global 3 phosphoinositide dependent protein kinase 1 Market
The North America region is expected to hold prominent share in the 3 phosphoinositide dependent protein kinase 1 market globally over the forecast period. The regional growth is attributable to the growing prevalence of breast cancer. According to the American Cancer Society, in 2022, about 287,850 new cases of invasive breast cancer will be diagnosed in women. About 51,400 new cases of ductal carcinoma in-situ (DCIS) had been diagnosed.
Market Players Outlook
The major companies serving the global 3 phosphoinositide dependent protein kinase 1 market include Boehringer Ingelheim GmbH, AstraZeneca PLC, Arno Therapeutics Inc., Sanofi SA, Novartis International AG, and others. To enhance their market share, industry participants are employing several critical techniques. For instance, in May 2019, Novartis International AG received an approval of Piqray (alpelisib) tablets from the USFDA. It is used in combination with the endocrine therapy fulvestrant for treating postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced, or metastatic breast cancer.BKX-001 as a potential treatment for leukaemia, lymphoma and solid tumours.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global 3 phosphoinositide dependent protein kinase 1 market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global 3 Phosphoinositide Dependent Protein Kinase 1 Market
• Recovery Scenario of Global 3 Phosphoinositide Dependent Protein Kinase 1 Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global 3 Phosphoinositide Dependent Protein Kinase 1 Market by Drug Type
4.1.1. HCI-1708
4.1.2. AR-12
4.1.3. PHT-427
4.1.4. SNS-229
4.1.5. Others
4.2. Global 3 Phosphoinositide Dependent Protein Kinase 1 Market by Application
4.2.1. Hospitals
4.2.2. Clinics
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Arno Therapeutics Inc.
6.2. AstraZeneca PLC
6.3. Bayer AG
6.4. Boehringer Ingelheim GmbH
6.5. Novartis International AG
6.6. Pfizer Inc.
6.7. Sanofi SA
6.8. Sunesis Pharmaceuticals Inc.
6.9. Tolero Pharmaceuticals Inc.
1. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
2. GLOBAL HCI-1708 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL AR-12 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL PHT-427 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL SNS-229 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL OTHERS 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
8. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
12. NORTH AMERICAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
14. NORTH AMERICAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
15. EUROPEAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. EUROPEAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
17. EUROPEAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET, 2021-2028 (%)
4. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY DRUG TYPE, 2021 VS 2027 (%)
5. GLOBAL HCI-1708 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL AR-12 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL PHT-427 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL SNS-229 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHERS 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
11. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN HOSPITALS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN CLINICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 IN OTHERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
17. UK 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
26. REST OF THE ASIA-PACIFIC 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF THE WORLD 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 MARKET SIZE, 2021-2028 ($ MILLION)
